Current Assets
Other Receivables
Eli Lilly Other Receivables increased by 14.7% to $2.75B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 39.7%, from $1.97B to $2.75B. Over 5 years (FY 2020 to FY 2025), Other Receivables shows an upward trend with a 17.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryLiquidity
SignalContext dependent
VolatilityStable
First reportedQ4 2015
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Significant fluctuations may indicate one-time events or changes in tax or regulatory accounting.
Detailed definition
This category captures miscellaneous amounts owed to the company that do not fall under standard trade accounts receivab...
Peer comparison
Commonly found in large, complex organizations with diverse global operations.
Metric ID:
other_receivablesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.07B | $1.11B | $1.45B | $1.48B | $1.31B | $1.61B | $1.66B | $1.50B | $1.66B | $2.20B | $2.25B | $2.13B | $2.05B | $1.76B | $2.27B | $1.97B | $3.04B | $3.35B | $2.40B | $2.75B |
| QoQ Change | — | +3.5% | +30.9% | +2.0% | -11.8% | +23.1% | +3.3% | -10.0% | +10.7% | +32.7% | +2.2% | -5.2% | -3.6% | -14.3% | +29.2% | -13.4% | +54.3% | +10.4% | -28.5% | +14.7% |
| YoY Change | — | — | — | — | +21.8% | +44.9% | +14.3% | +0.9% | +26.6% | +36.5% | +35.0% | +42.2% | +23.9% | -20.0% | +1.1% | -7.6% | +48.0% | +90.7% | +5.5% | +39.7% |
Range$1.07B – $3.35B
CAGR+21.9%
Avg YoY Growth+25.2%
Median YoY Growth+25.2%
Other Receivables at Other Companies
Frequently Asked Questions
- What is Eli Lilly's other receivables?
- Eli Lilly (LLY) reported other receivables of $2.75B in Q1 2026.
- How has Eli Lilly's other receivables changed year-over-year?
- Eli Lilly's other receivables increased by 39.7% year-over-year, from $1.97B to $2.75B.
- What is the long-term trend for Eli Lilly's other receivables?
- Over 5 years (2020 to 2025), Eli Lilly's other receivables has grown at a 17.8% compound annual growth rate (CAGR), from $1.05B to $2.40B.
- What does other receivables mean?
- Miscellaneous amounts owed to the company from sources other than regular customer sales.